The inhibition of TNFSF12, SLC22A4, and SPARC can reduce the risk of intracranial aneurysm, subarachnoid hemorrhage, and intracerebral hemorrhage. The gene discussed is SLC22A4; the disease is subarachnoid hemorrhage.